Mercy BioAnalytics, Inc.

We’re thrilled to announce the publication of two groundbreaking papers from Mercy BioAnalytics in the Journal of Molecular Diagnostics. The first describes our novel technology platform and the second, its initial application for early-stage ovarian cancer detection. The first publication, “Colocalization of cancer-associated biomarkers on single extracellular vesicles for early detection of cancer” details how our innovative Mercy Halo? technology enables the development of high-performance, low-cost cancer screening tests utilizing tumor associated extracellular-vesicle biomarkers. The second publication, “Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test – Performance in a training and verification cohort” describes the application of our platform for the early detection of ovarian cancer with high sensitivity and high specificity, suggesting it may be useful for population-based screening. These papers establish a strong foundation from which to build as we work to achieve our mission to reduce suffering and save lives through the early detection of cancer. They can be found in the following links: Paper 1:?https://lnkd.in/gPN2-kxK Paper 2:?https://lnkd.in/ghUipyUX https://lnkd.in/gPSTMCjh #MercyBio #OvarianCancer #EarlyDetection #CancerResearch

We’re wrapping up Ovarian Cancer Awareness Month with a purpose! On September 22nd, our team at Mercy Bio was honored to participate in the Boston Together in Teal 5K, joining forces with the National Ovarian Cancer Coalition and the ovarian cancer community to raise funding for education and awareness, research, community outreach, and quality of life support! We’re grateful for the opportunity to participate alongside so many incredible people and are committed to making a difference for those impacted by this devastating disease. Thank you to Danielle Sullivan for leading an incredible event! #OvarianCancerAwareness #CancerScreening #MercyBio #CancerResearch

Our amazing CEO, Dawn Mattoon, recently shared her inspiring story on HER SCRIPT with Cara Pepler! ? From humble beginnings to leading the charge at Mercy Bio, Dawn discusses her journey, lessons learned, and the drive that fuels her passion for helping patients everywhere. ? Listen here to learn more: https://lnkd.in/gkzHJb96 ? #MercyBio #Innovation #Leadership

We’re looking forward to the 15th Biennial Ovarian Cancer Research Symposium this week! ? On September 20th, come listen to CEO Dawn Mattoon present our latest data in ovarian cancer screening at 5:40pm in the Washington Ballroom. Then afterwards, stop by our poster, “Performance of an extracellular vesicle based ovarian cancer screening test in longitudinal preclinical samples from women with high grade serous ovarian cancer – an exploratory analysis“ and chat with lead author Sanchari Banerjee, Ph.D. Hope to see you there! #MercyBio #CancerScreening #OvarianCancer

The National Ovarian Cancer Audit Report, which was published earlier this week, includes some shocking statistics: 40% of the women diagnosed with ovarian cancer during the study had an ER admission within 28 days of their ovarian cancer diagnosis. Four in ten! Further, women diagnosed via an emergency presentation were 4X more likely to die within 2 months of their diagnosis than women diagnosed through the ‘urgent suspected referral system’ in the U.K. The study included more than 6,000 women in England and Wales who were diagnosed with ovarian cancer in 2021 or 2022, respectively. Unfortunately, but not unexpectedly, 75% of the ovarian cancers diagnosed were stage III or stage IV. The report urges efforts to improve awareness of signs and symptoms of ovarian cancer, and a review of diagnostic pathways. These are important objectives, but we need to go further. These statistics should be unacceptable, and I truly believe they are addressable. Mercy BioAnalytics, Inc. is fiercely committed to advancing our test designed for population screening of postmenopausal women in whom the majority of ovarian cancer occurs. We’re grateful to have received Breakthrough Device Designation from the FDA, and are now working diligently towards our PMA submission. I’m looking forward to discussing our progress at next week’s AACR Ovarian Cancer Research Summit! Find the NOCA's report here: https://lnkd.in/exQDG4Yd

The Mercy Team extends a huge thank you to Danielle Sullivan for visiting our office to launch Ovarian Cancer Awareness Month. We deeply appreciate her sharing insights about the incredible work the National Ovarian Cancer Coalition (NOCC) is doing for ovarian cancer patients and caregivers. We are excited about the chance to support the cause and look forward to joining the Together in Teal walk on September 22nd to help build community and raise awareness for ovarian cancer! September is Ovarian Cancer Awareness Month. Almost 20,000 women will be diagnosed with ovarian cancer this year alone. ? To learn more about ovarian cancer advocacy, visit?https://ovarian.org ? To learn more about the important advances in ovarian cancer detection being made by our team, visit?www.mercybio.com ? #NOCC #PatientAdvocacy #EarlyDetection #OvarianCancerAwarenessMonth

As Mercy’s summer internship program wraps up, we want to extend our heartfelt thanks to Arielle Feuer and Christopher O'Connell for all your hard work and commitment!? ? Over the past few months, you’ve brought enthusiasm, fresh perspectives, and dedication to team Mercy. We’re proud of the contributions you’ve made, and the skills you’ve developed during your time here. We're honored to have had you as part of the team! ? #MercyBio #SummerInterns #EarlyDetection #CancerScreening

Team Mercy took a break from revolutionizing cancer screening to enjoy some well-deserved summer fun and team bonding at Kimball Farms! We’re so grateful for the talented and dedicated individuals who make our team so special. Here’s to many more moments of fun and collaboration on the road to helping patients everywhere! #MercyBio #CancerScreening #SummerPicnic #Kimballfarms

August 1st?is Lung Cancer Awareness Day. Did you know that 1 in 16 people will be diagnosed with lung cancer in their lifetime and that 5-year survival is 10 times higher for people diagnosed with localized versus metastatic disease? Early detection is a critical tool to help combat the devastating impact of this disease. At Mercy, we are proud to be developing the Mercy Halo Lung Cancer assay; a high performance, blood-based test designed to detect lung cancer at its earliest stages, when it’s most treatable. ? To learn more about our research on the early detection of lung cancer please visit?www.mercybio.com To learn more about current methods for lung cancer screening, visit?https://lnkd.in/dZM9D6SY #worldlungcancerday #lungcancer #lungcancerawareness #cancerresearch #mercybio #earlycancerdetection

We’re pleased to share that we’ve been recognized by the Association for Diagnostics & Laboratory Medicine with the 2024 Disruptive Technology Award! This award aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care, such as the groundbreaking Mercy Halo? Ovarian Cancer Screening test, designed to detect ovarian cancer early when it’s most treatable. Congratulations to the other finalists, Dionysus Digital Health and Vitestro, whose technology has the potential to help patients everywhere. And thank you to Adam Bonislawski for the great article! https://lnkd.in/gtQw6k4P #DTAC #ADLM2024 #EarlyCancerDetection #CancerResearch